Form 4: IGMS Director Reports Share Disposition Post-Merger

A director of IGM Biosciences, Inc. reported the disposition of all shares following the company's merger into a wholly-owned subsidiary of Concentra Biosciences, LLC.

Summary

• M. Kathleen Behrens, a director of IGM Biosciences, Inc. (IGMS), reported the disposition of 412,535 shares of common stock.
• This transaction occurred on August 14, 2025, as a result of the merger of IGM Biosciences, Inc. with Concentra Merger Sub V, Inc., a wholly-owned subsidiary of Concentra Biosciences, LLC.
• In connection with the merger, each outstanding share of IGM Biosciences' Common Stock was cancelled and converted into the right to receive $1.247 in cash and one contractual contingent value right (CVR).
• Following the transaction, M. Kathleen Behrens holds 0 shares of IGM Biosciences, Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive for shareholders who received cash and a CVR, but the company ceased to be independent. The CVR introduces uncertainty, preventing a higher score.

Positives

• Shareholders received a cash payment of $1.247 per share, providing immediate liquidity.
• Shareholders also received a Contingent Value Right (CVR), offering potential future value based on specific milestones or events.

Negatives

• IGM Biosciences, Inc. ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary, which means existing shareholders no longer hold equity in the company.
• The value of the CVR is contingent and uncertain, dependent on future events and terms of the CVR Agreement.

Risks

• The value of the Contingent Value Right (CVR) is uncertain and dependent on future events, which may not materialize, potentially rendering the CVR worthless.
• Shareholders no longer participate in the future growth or decline of IGM Biosciences as an independent entity.

Future Outlook

The filing indicates the completion of a merger where IGM Biosciences, Inc. became a wholly-owned subsidiary of Concentra Biosciences, LLC. Future value for former shareholders is tied to the performance of the Contingent Value Rights (CVRs).

Industry Context

This merger signifies consolidation within the biotechnology sector, where smaller companies are often acquired by larger entities for their pipeline assets or technology. The use of a Contingent Value Right (CVR) is a common mechanism in biotech mergers to bridge valuation gaps, especially for assets with uncertain future milestones.

Comparison to Industry Standards

• The use of a CVR in biotech mergers is a standard practice, particularly when the acquired company has clinical-stage assets or uncertain future milestones. For example, similar structures have been seen in deals like the acquisition of Acceleron Pharma by Merck, where CVRs were used for specific drug candidates.
• The cash component of $1.247 per share would need to be evaluated against the company's pre-merger trading price and analyst price targets to assess its fairness relative to comparable biotech acquisitions.

Management Changes

Corporate Governance

Legal Proceedings

• No new legal proceedings were mentioned in this filing.

Related Party Transactions

• The filing details the disposition of shares held by trusts (KBW 2005 Trust, Non-Exempt Trust for Patrick R. Wilsey, Non-Exempt Trust for Shannon K. Wilsey) for which the reporting person, M. Kathleen Behrens, is a trustee. These represent related party holdings being liquidated as part of the merger.

Stakeholder Impact

• Shareholders: Received cash and CVRs, losing direct equity in the company.
• Employees: Likely to experience integration into Concentra Biosciences, LLC, with potential changes in roles or structure.
• Customers/Suppliers: Operations may be integrated or streamlined under the new parent company.

Next Steps

• Former shareholders will await potential payouts from the Contingent Value Rights (CVRs) based on the terms of the CVR Agreement.
• IGM Biosciences, Inc. will operate as a wholly-owned subsidiary of Concentra Biosciences, LLC.

Key Dates

Keywords

IGM Biosciences, IGMS, Merger, Acquisition, Form 4, Insider Trading, Contingent Value Right, CVR, Biotechnology, Corporate Action